Heart Failure Clinical Trial
— DecongestOfficial title:
The Significance of the Vasopressin System of the Hemodynamics, Water Balance and Prognosis in Chronic Heart Failure
The purpose of this study is to determine the effect of fluid restriction and the neurohormonal mechanisms in the development of hyponatremia in patients with congestive heart failure and hyponatremia. The hypothesis is that strict fluid restriction leads to a larger increase in plasma sodium than standard treatment in patients with decompensated heart failure associated with hyponatremia. A secondary hypothesis is that the neurohormonal change is greater in patients treated with strict fluid restriction versus standard treatment.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age > 18 years - Left Ventricular Ejection Fraction (LVEF) < 40 At least two of the following signs of decompensated heart failure and fluid retention: - Weight gain > 2 kg - Pulmonal Congestion - Jugular vein congestion - Peripheral oedemas - Hepatic congestion with ascites - Radiographic signs of fluid retention - Increased diuretic dose And - New York Heart Association (NYHA) class III-IV - Plasma sodium < 135 mmol/L - Symptomatic heart failure and treatment with relevant heart failure medications (beta-blocker, diuretic, digoxin, angiotensin-converting-enzyme inhibitor, angiotensin-II receptor antagonist, spironolactone, hydralazine and/or nitrates)for at least 1 month - Hospitalization for decompensated heart failure within the last 48 hours - Given informed consent Exclusion Criteria: - Plasma sodium = 135 mmol/L before randomization - Reduced kidney function (creatinine > 200 µmol/L) - Severe hematologic disease - Hypovolemic hyponatremia (volume depletion or dehydration) - Intolerability to large or fast changes in fluid volume assessed by the investigator - Plasma sodium < 120 mmol/L accompanied by neurologic symptoms - Anuria - Symptomatic systolic blood pressure (supine systolic blood pressure < 90 mmHg) - Uncontrolled hypertension (systolic blood pressure > 180 mmHg) - Uncontrolled diabetes diabetes mellitus - Adrenal insufficiency - Acute myocardial infarction, sustained ventricular tachycardia or ventricular fibrillation within the last 30 days - Heart surgery within the last 60 days - Other severe heart disease: hypertrophic cardiomyopathy, severe heart valve disease, cardiac amyloidosis, active myocarditis, pericardial exudate which is hemodynamically significant - Left ventricular assist device (LVAD) - Planned revascularization procedure, electrophysiologic device implantation, mechanic left ventricular assist device, heart transplant or any other heart surgery procedures within the next 30 days - Cerebrovascular event within the last 6 months - Comorbidity with an expected survival < 6 months - Other reasons for hyponatremia: Primary syndrome of inappropriate antidiuretic hormone secretion (SIADH), primary polydipsia, head trauma, uncontrolled hypothyroidism, adrenal insufficiency or other known pharmacologically triggered hyponatremia which is reversible upon discontinuation of the drug, hyperglycemia (pseudohyponatremia), present abuse of alcohol - Pregnancy - Pregnant or fertile women who are not using safe contraception - Dementia - Unwilling or unable to give informed consent |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Bispebjerg Hospital | Copenhagen | |
Denmark | Department of Cardiology, Copenhagen University Hospital, Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Finn Gustafsson | Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in plasma sodium from day 1 to day 4: - Normalization of plasma sodium or - A significant change in plasma sodium of a minimum of 5 mmol/L from baseline to day 4 | 5 days | Yes | |
Secondary | Change in plasma vasopressin and copeptin | 5 days | No | |
Secondary | Change in blood pressure, heart rate, weight and oedemas | 5 days | No | |
Secondary | Change in dyspnoea assessed by the patient | 5 days | No | |
Secondary | Number of days until clinical stability | 5 days | No | |
Secondary | The correlation between hospitalization time and plasma sodium | 5 days | Yes | |
Secondary | Correlation between fluid restriction and change in kidney function | 5 days | Yes | |
Secondary | Patient assessment of fluid restriction | 5 days | No | |
Secondary | Patient compliance to fluid restriction | 5 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|